Relieves occasional sleeplessness. NDA 205352, held by Bayer Hlthcare. Diphenhydramine Hydrochloride; Naproxen Sodium.
As of Nov 16, 2026, NDA 205352 (Aleve Pm), held by Bayer Hlthcare, was first approved by FDA on Jan 17, 2014, with 14 approved supplements and 0 published complete response letters.
Uses for relief of occasional sleeplessness when associated with minor aches and pains helps you fall asleep and stay asleep
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 17, 2014 | Original applicationNew combination · Standard review | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Aleve Pm25MG;220MG · tablet;oral | Diphenhydramine Hydrochloride; Naproxen Sodium | OTCReference drug |
| Feb 8, 2022 | Supplement 16Labeling · Standard review | Approved | |
| Oct 30, 2020 | Supplement 15Labeling · Standard review | Approved | |
| Apr 6, 2020 | Supplement 14Labeling · Standard review | Approved | |
| Apr 10, 2019 | Supplement 13Labeling · Standard review | Approved | |
| Aug 28, 2018 | Supplement 11Labeling · Standard review | Approved | |
| Jan 16, 2018 | Supplement 10Labeling · Standard review | Approved | |
| Sep 12, 2017 | Supplement 9Labeling · Standard review | Approved | |
| Dec 23, 2015 | Supplement 7Manufacturing · Standard review | Approved | |
| Oct 28, 2015 | Supplement 6Labeling · Standard review | Approved | |
| Aug 14, 2015 | Supplement 5Labeling · Standard review | Approved | |
| Jul 15, 2015 | Supplement 4Labeling · Standard review | Approved | |
| Feb 25, 2015 | Supplement 3Labeling · Standard review | Approved | |
| Nov 20, 2014 | Supplement 2Labeling · Standard review | Approved | |
| Aug 28, 2014 | Supplement 1Labeling · Standard review | Approved | |
| Jan 17, 2014 | Original applicationNew combination · Standard review | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters